Cancer takes 10 million lives yearly, and late-stage diagnosis is often to blame. Early detection significantly improves survival rates, yet current screening methods are inaccessible to many or not sensitive enough to catch cancers early. Mammograms miss around 12% of breast cancers, and even advanced 3D mammograms produce false positives in 50% of women over a ten-year span. Worse, cancers in organs like the liver, pancreas, and ovaries often have no reliable screening, leading to diagnoses too late for effective treatment.
Oncoliq's Mission and Cutting-Edge Approach
Oncoliq's mission is clear: reduce cancer mortality by addressing the root cause—late detection. "At Oncoliq, we've developed a solution that can change the landscape of cancer diagnostics, making it possible to detect cancer early, easily, and at a low cost," says Marina Simian, the company's co-founder and CEO. Oncoliq uses cutting-edge technology to make early detection accessible, improving outcomes for millions.
MicroRNA Detection: The Key to Early Diagnosis
Early detection through microRNA offers a key advantage with superior accuracy. Oncoliq's blood test detects microRNA, tiny molecules present in the early stages of tumor development. This is what differentiates Oncoliq from competitors who rely on detecting ctDNA, which only appears in the bloodstream during later stages of cancer. In addition to this early detection capability, Oncoliq's method achieves high sensitivity and specificity, offering reliable results. By targeting these early-stage markers with superior accuracy, Oncoliq provides a potentially life-saving advantage in detecting cancer before it progresses.
Leveraging existing PCR technology makes Oncoliq's test scalable and cost-effective. The solution is built on widely available PCR machines, which amplify genetic material, making it easier to detect microRNAs. This technology is already present in thousands of labs globally, making the test not only accurate but also decentralized and scalable, ideal for mass adoption.
Practical and Scalable Cancer Screening
Oncoliq eliminates logistical hurdles by extending sample viability. Blood samples can be stored at room temperature for up to 48 hours, far longer than traditional tests, which often require analysis within hours to avoid degradation. This innovation makes Oncoliq's test more practical for large-scale cancer screenings, especially in regions with limited infrastructure.
Oncoliq's focus is on launching its product by early 2026, targeting private clients seeking deeper health insights. The initial launch as an LDT (Laboratory Developed Test) will cater to private clients interested in gaining more detailed information about their health. Alongside this, Oncoliq will work with the FDA to begin clinical studies aimed at securing regulatory approval. The dual approach ensures both immediate market presence and long-term validation through clinical trials.
The cost-effectiveness of Oncoliq's test makes it a game-changer in cancer diagnostics. Traditional cancer screening methods like mammograms or colonoscopies are expensive and often inaccessible, while Oncoliq's test uses affordable PCR technology. This allows it to be offered at a fraction of the cost, paving the way for mass screening programs, especially in areas where healthcare resources are limited.
The expertise behind Oncoliq is a major asset. Oncoliq is powered by a founding team with deep experience in cancer biology and business. CEO Marina Simian and CSO Adriana De Siervi both have extensive backgrounds in cancer research, while Osvaldo Pontiggia brings commercial expertise from leadership roles at Sanofi, Genzyme, and AstraZeneca. Together, they've built a company grounded in rigorous research and a mission to save lives.
Investor Support and Path to Global Leadership
Investor support reflects Oncoliq's immense potential to transform cancer detection. Oncoliq has already attracted significant financial backing, raising $1.67 million in research grants, securing $300K in pre-seed investment, and receiving $540K in bridge funding backed by investors like Draper University Ventures, Air Capital, and SF500.
Oncoliq is poised to be a global leader in cancer diagnostics. As the company moves towards FDA approval and U.S. commercialization in 2026, it is on track to deliver a scalable, decentralized solution to one of healthcare's biggest challenges—early cancer detection. With its unique ability to detect cancer early, easily, and affordably, Oncoliq is ready to make a massive impact on global cancer mortality.
Join Oncoliq in shaping the future of cancer detection and saving lives. For investors seeking a high-impact opportunity in healthcare, Oncoliq offers a unique combination of cutting-edge technology, proven leadership, and a clear path to global scalability. Oncoliq is currently raising its SEED round. "The strong financial traction we've seen reflects the immense potential of our solution," says Simian. "We're looking for investors who share our vision and want to support a scalable, high-impact solution that can dramatically reduce cancer mortality."
Join the Conversation